AbbVie - ABBV Stock Forecast, Price & News

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 7 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ABBV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABBV, but not buy additional shares or sell existing shares.
View ABBV analyst ratings or view top-rated stocks.

15 Wall Street research analysts have issued twelve-month price objectives for AbbVie's shares. Their ABBV share price forecasts range from $135.00 to $200.00. On average, they anticipate the company's stock price to reach $158.56 in the next year. This suggests that the stock has a possible downside of 1.6%.
View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts.

AbbVie's stock was trading at $135.40 at the start of the year. Since then, ABBV shares have increased by 19.0% and is now trading at $161.18.
View the best growth stocks for 2022 here.

AbbVie saw a increase in short interest in October. As of October 15th, there was short interest totaling 14,000,000 shares, an increase of 5.3% from the September 30th total of 13,290,000 shares. Based on an average daily trading volume, of 5,420,000 shares, the short-interest ratio is presently 2.6 days.
View AbbVie's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 1st 2023.
View our ABBV earnings forecast.

AbbVie Inc. (NYSE:ABBV) posted its quarterly earnings data on Friday, October, 28th. The company reported $3.66 EPS for the quarter, topping analysts' consensus estimates of $3.57 by $0.09. The company had revenue of $14.81 billion for the quarter, compared to the consensus estimate of $14.95 billion. AbbVie had a trailing twelve-month return on equity of 155.88% and a net margin of 23.19%. AbbVie's revenue for the quarter was up 3.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.33 EPS.
Read the conference call transcript.

AbbVie announced a quarterly dividend on Friday, October 28th. Investors of record on Friday, January 13th will be given a dividend of $1.48 per share on Wednesday, February 15th. This represents a $5.92 annualized dividend and a yield of 3.67%. The ex-dividend date of this dividend is Thursday, January 12th. This is a positive change from the stock's previous quarterly dividend of $1.41.
Read our dividend analysis for ABBV.

AbbVie (NYSE:ABBV) pays an annual dividend of $5.64 per share and currently has a dividend yield of 3.57%. The company has been increasing its dividend for 50 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 75.30%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 49.39% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ABBV.

AbbVie issued an update on its fourth quarter 2022 earnings guidance on Sunday, November, 6th. The company provided EPS guidance of $3.65-$3.69 for the period, compared to the consensus earnings per share estimate of $3.75. The company issued revenue guidance of $15.20 billion-$15.20 billion, compared to the consensus revenue estimate of $15.78 billion.

580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX).

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.82%), BlackRock Inc. (7.52%), State Street Corp (4.38%), Price T Rowe Associates Inc. MD (1.39%), Bank of New York Mellon Corp (1.17%) and Nuveen Asset Management LLC (0.77%). Insiders that own company stock include Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Edward J Rapp, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and Timothy J Richmond.
View institutional ownership trends.

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABBV stock can currently be purchased for approximately $161.18.

AbbVie (NYSE:ABBV) has a market capitalization of $285.04 billion and generates $56.20 billion in revenue each year. The company earns $11.54 billion in net income (profit) each year or $7.49 on an earnings per share basis.

The company employs 50,000 workers across the globe.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The official website for the company is www.abbvie.com. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049.